Feasibility of using PALSAR technology as a signal amplifier for antibody bridging assay

Review Medicine, Research & Experimental

Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018

Hobart Rogers et al.

Summary: The research focused on assessing the performance of oligonucleotide therapies in terms of drug-drug interactions, organ impairment, immunogenicity, and cardiac safety. Limited data were available regarding organ impairment, but the assessment of drug-drug interaction potential aligned with current recommendations.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Recent Advances in Oligonucleotide Therapeutics in Oncology

Haoyu Xiong et al.

Summary: Oligonucleotide therapeutics show promising clinical outcomes in diseases such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. Although no approved oligonucleotide drug exists for any type of cancer, results from preclinical studies and clinical trials are encouraging.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Nanoscience & Nanotechnology

The current landscape of nucleic acid therapeutics

Jayesh A. Kulkarni et al.

Summary: The increasing number of approved nucleic acid therapeutics demonstrates their potential for long-lasting or curative effects by targeting genetic blueprints; however, their clinical translation relies on advances in delivery technologies. Four platform technologies, including antisense oligonucleotides, small interfering RNA conjugates, lipid nanoparticles, and adeno-associated virus vectors, have enabled the clinical translation of nucleic acid therapeutics, leading to the approval of cutting-edge genetic drugs.

NATURE NANOTECHNOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain

Derrick Johnson et al.

Summary: The evaluation of unwanted immunogenicity plays a key role in the clinical safety assessment of new biotherapeutic drugs and macromolecular delivery strategies. Through systematic optimization of the direct binding assay, a sensitive and reliable method for detecting serum anti-drug antibodies has been developed for regulatory-compliant assays.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Editorial Material Biochemical Research Methods